SCHEMBL11931409

SCHEMBL11931409

COC(=O)C(C)C1CCCN(C(=O)OC(C)(C)C)C1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 1/20 0.49
ALDH1A1 P00352 3/20 0.47
MAPT P10636 2/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
HPGD P15428 1/20 0.45
USP30 Q70CQ3 4/20 0.43
NPC1 O15118 1/20 0.43
MAPK1 P28482 1/20 0.43
HTT P42858 1/20 0.43
RAB9A P51151 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
GPR119 Q8TDV5 2/20 0.42
JAK2 O60674 1/20 0.42
JAK1 P23458 1/20 0.42
TRPV3 Q8NET8 1/20 0.42
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
GLS O94925 1/20 0.39
PREP P48147 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30835882 0.92 GPR119 (0.49) EPHX1ALDH1A1MAPTMEN1KMT2A
SCHEMBL21800531 0.92 GPR119 (0.49) EPHX1ALDH1A1MAPTMEN1KMT2A
SCHEMBL1556017 0.88 ALDH1A1 (0.46) EPHX1ALDH1A1MAPTMEN1KMT2A
SCHEMBL1422180 0.86 ALDH1A1 (0.49) EPHX1ALDH1A1MAPTMEN1KMT2A
SCHEMBL12125458 0.84 ALDH1A1 (0.52) EPHX1ALDH1A1MAPTMEN1KMT2A
SCHEMBL25597565 0.84 ALDH1A1 (0.52) EPHX1ALDH1A1MAPTMEN1KMT2A
SCHEMBL12384596 0.84 ALDH1A1 (0.52) EPHX1ALDH1A1MAPTMEN1KMT2A
SCHEMBL13400340 0.83 ALDH1A1 (0.51) EPHX1ALDH1A1MAPTMEN1KMT2A
SCHEMBL7934588 0.83 ALDH1A1 (0.51) EPHX1ALDH1A1MAPTMEN1KMT2A
SCHEMBL3821259 0.83 EPHX1 (0.54) EPHX1ALDH1A1MAPTHPGDNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2069349-B1 PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS MERCK SHARP & DOHME (US) 2016-06-15 EP disclosed
EP-1942900-B1 USE OF PYRAZOLO [1,5-A] PYRIMIDINE DERIVATIVES FOR INHIBITING KINASES METHODS FOR INHIBITING PROTEIN KINASES MERCK SHARP & DOHME (US) 2015-06-03 EP disclosed
US-8211854-B2 Methods for inhibiting protein kinases SCHERING CORPORATION (US) 2012-07-03 US disclosed
US-8211854-B2 Methods for inhibiting protein kinases SCHERING CORPORATION (US) 2012-07-03 US disclosed
US-20100125068-A1 METHODS FOR INHIBITING PROTEIN KINASES SCHERING CORPORATION 2010-05-20 US disclosed
US-20100125068-A1 METHODS FOR INHIBITING PROTEIN KINASES SCHERING CORPORATION 2010-05-20 US disclosed
US-7605155-B2 Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors SCHERING CORPORATION (US) 2009-10-20 US disclosed
US-7605155-B2 Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors SCHERING CORPORATION (US) 2009-10-20 US disclosed
US-20070082900-A1 Methods for inhibiting protein kinases SCHERING CORPORATION 2007-04-12 US disclosed
US-20070072881-A1 Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors SCHERING CORPORATION 2007-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070082900-A1 Methods for inhibiting protein kinases PIM1, AURKC, PIM3 EPHX1 3422/4885ALDH1A1 3457/4885MAPT 2170/4885
US-20100125068-A1 METHODS FOR INHIBITING PROTEIN KINASES PIM1, AURKC, PIM3 EPHX1 3422/4885ALDH1A1 3457/4885MAPT 2170/4885
US-20070072881-A1 Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors CDK2, CDK1, CDKN1A EPHX1 1943/4885ALDH1A1 2628/4885MAPT 2958/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.